UBS Maintains Buy on Eli Lilly and Company (LLY) March 18, 2026

UBS maintained a Buy rating on Eli Lilly and Company (LLY) on March 18, 2026. The move anchors the current LLY analyst rating discussion because UBS cited strong fourth-quarter results and raised upside guidance. UBS reiterated its stance in a research note covered by StreetInsider and left the rating unchanged at Buy. Investors should note the stated 4.08% move and $37.38 change since the note. This note is one data point among many for LLY analyst rating and helps frame near-term market expectations.

LLY analyst rating: UBS action and rationale

On March 18, 2026 UBS maintained Buy on Eli Lilly and Company (LLY). UBS pointed to strong Q4 results and raised guidance as core reasons for holding the Buy rating. The firm did not publish a new price target in the StreetInsider summary but kept its bullish stance.

LLY analyst rating: Recent analyst price target moves

Other firms moved targets recently, showing mixed signals for Eli Lilly and Company analyst rating. Guggenheim set a $1,163 12-month price target on March 30, 2026, implying about 21.38% upside source. Freedom Broker raised its target to $1,200 on February 10, 2026, while HSBC cut its target from $1,070 to $850 on March 17, 2026.

LLY analyst rating: What maintained Buy means for investors

A maintained Buy signals that UBS sees continued growth and earnings momentum for Eli Lilly and Company. For investors, the call suggests holding or adding on weakness, not selling. This stance should be balanced against recent target cuts from other firms.

LLY analyst rating: Market reaction and metrics

Market moves around the UBS note show modest gains, roughly 4.08% or $37.38 since the publication. Eli Lilly’s market capitalization stands at $901,621,875,320, reflecting the company’s scale and influence in healthcare equities.

LLY analyst rating: Historical analyst coverage context

LLY has broad coverage with about 50 analyst firms reporting ratings in the past year, per Benzinga source. Analysts typically refresh views quarterly after earnings calls, producing frequent updates like the UBS reiteration.

LLY analyst rating: How Meyka AI frames the call

Meyka AI rates LLY with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and are not financial advice, but they provide a structured view alongside analyst opinions.

Final Thoughts

UBS’s March 18, 2026 decision to maintain a Buy on Eli Lilly and Company (LLY) keeps a major voice positive on the stock. The UBS note supports the current LLY analyst rating narrative by citing strong Q4 performance and upside guidance. Investors should weigh this maintained Buy against recent mixed price-target moves, including Guggenheim’s $1,163 target, Freedom Broker’s $1,200 raise, and HSBC’s cut to $850. LLY’s large market cap of $901,621,875,320 keeps it central to healthcare portfolios, and the stock’s moves since the UBS note show modest upside near 4.08% or $37.38. Use Meyka AI’s grade and the broader analyst mix to form a balanced view. Meyka AI provides this AI-powered market analysis as context, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.